Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation

Pediatr Blood Cancer. 2010 Sep;55(3):577-9. doi: 10.1002/pbc.22542.

Abstract

We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ). The patient had no family history of malignancy except her grand father and his siblings. Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas. We demonstrate a rare case of TMZ-related ALL in a child with glioma possibly associated with a germline TP53 mutation.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Astrocytoma / drug therapy*
  • Astrocytoma / genetics
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / genetics
  • Child
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Female
  • Frontal Lobe*
  • Genes, p53 / genetics*
  • Germ-Line Mutation*
  • Humans
  • Neoplasms, Second Primary / chemically induced*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced*
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide